

WHAT IS CLAIMED IS:

1. A DNA segment comprising an AAV *rep* coding sequence operably linked to a promoter, an AAV *cap* coding sequence operably linked to a promoter, an HSV-1 origin of replication and an HSV-1 packaging sequence.
2. The DNA segment of claim 1, wherein said AAV *rep* coding sequence or said AAV *cap* coding sequence is operably linked to a p5, p19 or p40 promoter.
3. The DNA segment of claim 2, wherein said AAV *rep* coding sequence and said AAV *cap* coding sequence are operably linked to a p5, p19 or p40 promoter.
4. The DNA segment of claim 1, comprised within a recombinant herpes simplex virus vector.
5. The DNA segment of claim 1, comprised within a recombinant herpes simplex virus capsid.
6. A recombinant herpes simplex virus vector comprising an AAV *rep* coding sequence operably linked to a promoter and an AAV *cap* coding sequence operably linked to a promoter.
7. The recombinant vector of claim 6, wherein said AAV *rep* coding sequence or said AAV *cap* coding sequence is operably linked to a p5, p19 or p40 promoter.

8. The recombinant vector of claim 6, in which a non-essential HSV gene is altered.

9. The recombinant vector of claim 8, in which a non-essential HSV gene is altered to increase expression.

10. The recombinant vector of claim 9, in which said non-essential HSV gene encodes ICP8.

11. The recombinant vector of claim 8, in which a non-essential HSV gene is mutated or substantially deleted.

12. The recombinant vector of claim 11, in which a non-essential HSV gene is substantially deleted.

13. The recombinant vector of claim 12, in which said non-essential HSV gene encodes ICP27 or glycoprotein H.

14. The recombinant vector of claim 13, in which said non-essential HSV gene encodes ICP27.

15. The recombinant vector of claim 6, comprised within a recombinant herpes simplex virus.

16. A recombinant herpes simplex virus comprising an AAV *rep* coding sequence operably linked to a promoter and an AAV *cap* coding sequence operably linked to a promoter.

17. The recombinant virus of claim 16, wherein said AAV *rep* coding sequence or said AAV *cap* coding sequence is operably linked to a p5, p19 or p40 promoter.

18. The recombinant virus of claim 16, in which a non-essential HSV gene is altered.

19. The recombinant virus of claim 16, wherein said recombinant virus is the d27.1rc virus.

20. A kit comprising, in a suitable container, a DNA segment comprising an AAV *rep* coding sequence operably linked to a promoter, an AAV *cap* coding sequence operably linked to a promoter, an HSV-1 origin of replication and an HSV-1 packaging sequence.

21. The kit of claim 21, further comprising an HSV-1 helper virus.

22. The kit of claim 21, in which a non-essential gene of said HSV-1 helper virus is altered.

23

24. The kit of claim 21, wherein said HSV-1 helper virus is the d27.1 HSV-1 virus.

5

24

25. A kit comprising, in a suitable container, a recombinant herpes simplex virus vector comprising an AAV *rep* coding sequence operably linked to a promoter and an AAV *cap* coding sequence operably linked to a promoter.

10

25

26. The kit of claim 25, wherein said recombinant herpes simplex virus vector is comprised in a recombinant herpes simplex virus.

15

26

27. The kit of claim 26, in which a non-essential gene of said recombinant herpes simplex virus is altered.

20

27

28. The kit of claim 26, wherein said recombinant herpes simplex virus is the d27.1rc HSV-1 virus.

28

29. A method for preparing a rAAV comprising:

25

a) providing an HSV-1 helper virus and a DNA segment comprising an AAV *rep* coding sequence operably linked to a promoter, an AAV *cap* coding sequence operably linked to a promoter, an HSV-1 origin of replication and an HSV-1 packaging sequence to a host cell that comprises a rAAV;

30

- b) culturing said cell under conditions effective to produce rAAV in said cell; and
- c) obtaining said rAAV from said cell.

5

29  
30. The method of claim 29, wherein said host cell comprises said rAAV integrated into the genome of said cell.

10

30  
31. The method of claim 29, wherein said host cell is provided with said rAAV, said HSV-1 helper virus and said DNA segment simultaneously.

15

31  
32. The method of claim 29, wherein said host cell is a HeLa, 293 or Vero cell.

32  
33. The method of claim 29, wherein said rAAV comprises a therapeutic gene.

20

33  
34. A recombinant AAV virus produced by the method of claim 29.

25

34  
35. A kit comprising, in a suitable container, a recombinant AAV virus produced by the method of claim 29.

30

35  
36. A method for preparing a rAAV comprising:

a) providing a recombinant herpes simplex virus that comprises an AAV *rep* coding sequence operably linked to a promoter and an AAV *cap*

coding sequence operably linked to a promoter to a host cell that comprises a rAAV;

- b) culturing said cell under conditions effective to produce rAAV in said cell; and
- c) obtaining said rAAV from said cell.

10 <sup>36</sup>  
~~37~~. The method of claim 36, wherein said host cell comprises said rAAV integrated into the genome of said cell.

15 <sup>37</sup>  
~~38~~. The method of claim 36, wherein said host cell is provided with said rAAV and said recombinant herpes simplex virus simultaneously.

20 <sup>38</sup>  
~~39~~. The method of claim 36, wherein said rAAV comprises a therapeutic gene.

25 <sup>39</sup>  
~~40~~. A recombinant AAV virus produced by the method of claim 36.

30 <sup>40</sup>  
~~41~~. A kit comprising in a suitable container, a recombinant AAV virus produced by the method of claim 36.

add C1  
add C2  
add D5